Skip to main content

Table 4 Summary of tremelimumab pharmacokinetic parameter values following a 1-hour intravenous infusion in comparison with those following a 5 -hour intravenous infusion in A3671008 Study

From: Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

 

A3671022 Study

A3671008 Study

 

Cmax

AUCinf (μg*h/mL)

t1/2

Cmax

AUCinf (μg*h/mL)

t1/2

 

(μg/mL)

 

(days)

(μg/mL)

 

(days)

N

42

32

32

150

150

150

Mean

322

104500

19.6

329

112719

19.2

SD

62

32400

5.7

112

40933

5.9